The U.S. Food and Drug Administration Approves Mosunetuzumab-axgb (Lunsumio) for Follicular Lymphoma
On December 22, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific antibody, for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two or more…